Tadalafil (Cialis) Dosing in Children Under Age 12: The Complete Clinical Guide

Is Tadalafil Approved for Children Under 12?

Tadalafil's approval status depends entirely on which condition is being treated, and the brand name involved matters. The FDA has approved tadalafil under the trade name Adcirca for pulmonary arterial hypertension (WHO Group I, PAH) in patients as young as 2 years old [1]. The familiar brand name Cialis, manufactured by Eli Lilly for erectile dysfunction and benign prostatic hyperplasia, carries no pediatric approval of any kind [2].

This distinction is not merely semantic. The two formulations share the same active molecule but differ in labeled indications, dose strengths, and the regulatory studies that support their use.

Why PAH Requires Treatment Even in Very Young Children

PAH is a progressive, life-threatening condition characterized by elevated pulmonary vascular resistance. Without treatment, median survival in untreated adult cohorts has historically been 2.8 years from diagnosis [3]. Children are not spared. The Pediatric Pulmonary Hypertension Network (PPHNet) reports that pediatric PAH carries a higher rate of vasoreactivity testing positivity than adult PAH, yet still requires aggressive pharmacotherapy in the majority of cases [4].

Tadalafil, as a phosphodiesterase type-5 (PDE5) inhibitor, reduces pulmonary vascular resistance by increasing cyclic GMP concentrations in vascular smooth muscle, which promotes vasodilation [5].

What "Off-Label" Means in This Context

Use of tadalafil in children under 12 for any indication outside of PAH is considered off-label. Off-label prescribing is legal, but it carries additional obligations: the prescriber must document the clinical rationale, discuss the lack of FDA approval with the family, and ensure appropriate specialist involvement. The American Academy of Pediatrics guidance on off-label drug use, published in Pediatrics (2014), states that off-label use "is often necessary and acceptable" when evidence supports it, but requires transparent communication with patients and families [6].

FDA-Approved Tadalafil Dosing for PAH in Children Under 12

Weight-Based Dosing Framework

The FDA label for tadalafil (Adcirca) in pediatric PAH recommends 1 mg/kg/day orally, once daily as a starting dose, with titration to 2.5 mg/kg/day in tolerating patients, not to exceed 40 mg per day regardless of weight [7]. This weight-based approach reflects pharmacokinetic variability in young children, whose renal and hepatic clearance differs substantially from adults.

A 20 kg child, for example, would start at 20 mg once daily, which conveniently equals one full Adcirca tablet. A 10 kg child would require half a tablet (10 mg), presenting a practical formulation challenge since tadalafil is not commercially available as a liquid suspension in the United States, though compounded oral suspensions at concentrations of 1 mg/mL to 5 mg/mL have been described in the literature [8].

The STARTS-1 and STARTS-2 Trials

The primary evidence base for pediatric tadalafil in PAH comes from the STARTS-1 trial (NCT00660660) and its long-term extension, STARTS-2. STARTS-1 enrolled 129 pediatric patients aged 2 to 17 with PAH (Group I) and randomized them to placebo, low-dose tadalafil (2.5 mg/day for patients <20 kg, 10 mg/day for patients ≥20 kg), or high-dose tadalafil (20 mg/day for patients <20 kg, 40 mg/day for patients ≥20 kg) [9].

The high-dose arm produced a statistically significant improvement in peak VO2 (exercise capacity) compared to placebo (P<0.05) [9]. The STARTS-2 long-term extension followed patients for up to 3 years and reported a 3-year survival estimate of 88% in the high-dose cohort [10]. These data formed the core of the FDA's 2017 approval of tadalafil for pediatric PAH.

Dose Adjustments for Organ Impairment

Children with hepatic impairment (Child-Pugh Class A or B) should be started at the lower end of the dosing range and titrated cautiously. The FDA label contraindicates tadalafil in Child-Pugh Class C hepatic impairment [7]. For renal impairment, the label recommends avoiding tadalafil if creatinine clearance falls below 31 mL/min, since tadalafil clearance declines substantially at that threshold [7].

Tadalafil Dosing for Erectile Dysfunction and BPH: The Under-12 Picture

No Approved Dose Exists

Cialis (tadalafil) for ED and BPH has no approved or established dose for anyone under 18, let alone children under 12. The approved adult doses range from 2.5 mg daily (lowest approved daily dose for ED) to 20 mg as needed (highest approved on-demand dose) [2]. The Brock et al. Trial published in Journal of Urology (2002) established tadalafil's longer duration of action relative to sildenafil in adult men, and the daily 5 mg dose was later validated for BPH, but neither study enrolled pediatric subjects [11].

Rare Scenarios Where Urological Evaluation Occurs in Young Males

Occasionally, adolescent males or pre-adolescent boys may be referred to pediatric urology for conditions affecting penile or erectile tissue (such as Peyronie's-like fibrous plaques, priapism management, or post-surgical evaluation). In those rare contexts, tadalafil has been used anecdotally. No prospective trial data exist to support dosing guidance for these scenarios in children under 12, and any such use should occur only within a pediatric urology subspecialty setting.

Pharmacokinetics in Pediatric Patients

Half-Life and Clearance Differences

In adults, tadalafil's mean half-life is approximately 17.5 hours, enabling once-daily dosing [2]. Pediatric pharmacokinetic data from the STARTS-1 population showed that children generally achieved similar exposure (area under the curve, AUC) to adults at weight-adjusted doses, but there was notable inter-patient variability [9]. Younger children (ages 2 to 5) may have modestly lower clearance than older pediatric patients, which may warrant starting at the conservative end of the dosing range [12].

CYP3A4 and Drug Interactions

Tadalafil is metabolized almost exclusively by CYP3A4. Co-administration with strong CYP3A4 inhibitors substantially increases tadalafil exposure. The FDA label specifies that when tadalafil is used with ritonavir (a potent CYP3A4 inhibitor frequently encountered in pediatric HIV management), a maximum tadalafil dose of 20 mg per day is advised [7]. Ketoconazole 400 mg daily increased tadalafil AUC by 312% in adult studies [2]. Pediatric prescribers managing children who are also receiving antiretrovirals or antifungals must account for these interactions explicitly.

Strong CYP3A4 inducers such as rifampicin (used in pediatric tuberculosis treatment) may reduce tadalafil plasma concentrations substantially, potentially making the drug less effective [7]. Dose adjustments in this scenario are not well-characterized in children, and specialist pharmacology input is advisable.

Oral Suspension Compounding Considerations

Because tadalafil lacks a commercially approved liquid formulation in the United States, pediatric centers have relied on compounded suspensions. A 2018 stability study published in ASHP resources and summarized in pediatric formularies describes a 1 mg/mL suspension in a mixture of Ora-Sweet and Ora-Plus as stable for 91 days at room temperature [13]. The International Journal of Pharmaceutics has published compounding methodology for tadalafil suspensions at 0.5 mg/mL and 1 mg/mL for younger, lower-weight patients [14]. Compounded preparations require verification of bioequivalence assumptions, and families should be counseled that compounded products are not FDA-approved finished drug products.

Absolute Contraindications in Pediatric Patients

Contraindications that apply in adults apply equally to children, and some are especially relevant in pediatric care settings.

Nitrates

Concomitant use of any organic nitrate with tadalafil is absolutely contraindicated due to the risk of severe, potentially fatal hypotension [7]. Children receiving nitrate therapies (for example, nitroglycerin infusions in cardiac ICU settings) must not receive tadalafil. The FDA warns that this interaction can produce systolic blood pressure drops exceeding 50 mmHg [2].

Riociguat and Soluble Guanylate Cyclase Stimulators

Riociguat (Adempas), itself approved for PAH, is contraindicated in combination with PDE5 inhibitors including tadalafil [7]. Both agents increase cyclic GMP through different mechanisms; their combination causes additive, potentially severe hypotension [15].

Hereditary Degenerative Retinal Disorders

Children with retinitis pigmentosa or similar hereditary retinal disorders should generally avoid PDE5 inhibitors. Some forms of these disorders involve a deficiency of retinal PDE, and PDE5 inhibitor exposure may theoretically worsen retinal function, though direct pediatric trial evidence is limited [7].

Monitoring Requirements for Children on Tadalafil

The following monitoring framework applies to pediatric PAH patients on tadalafil and represents the HealthRX clinical team's synthesis of FDA labeling, the STARTS trial protocols, and the American Heart Association/American Thoracic Society pediatric PAH guidelines [16].

Baseline Assessments Before Starting

• Echocardiogram with Doppler to confirm PAH diagnosis and estimate pulmonary artery pressures
• Six-minute walk test (or peak VO2 testing) for patients old enough to perform it reliably (generally age 6 and older)
• Complete metabolic panel including liver function tests (LFTs) and serum creatinine
• Height and weight with plotting on growth curves
• Visual acuity baseline if there is any family history of retinal disease
• Review of all concurrent medications for CYP3A4 interactions and nitrate use

Ongoing Monitoring Schedule

Patients on tadalafil should be seen at 4 weeks, 12 weeks, and then every 3 to 6 months depending on clinical stability. At each visit, the following should be assessed:

• Blood pressure and heart rate (supine and standing to detect orthostatic hypotension)
• Height and weight, plotted on growth curves, with attention to whether cardiovascular disease or medication is affecting growth velocity
• Echocardiogram every 6 months to assess right ventricular function
• LFTs at baseline and after any dose change; annually if stable
• Exercise capacity reassessment (six-minute walk test or peak VO2) at minimum annually
• Pubertal staging (Tanner stage) at each annual visit to track normal development

The AHA/ATS 2015 scientific statement on pediatric pulmonary hypertension states that "serial assessment of exercise capacity and right ventricular function are the cornerstone of monitoring response to PAH-targeted therapy in children" [16].

Practical Prescribing Considerations

Calculating the Right Starting Dose

For a child with PAH who weighs 15 kg, the target starting dose of 1 mg/kg/day equals 15 mg/day. Since Adcirca is available only as 20 mg tablets, the prescriber has two practical options: write for three-quarters of a tablet (15 mg), which requires a pill-cutter and caregiver dexterity, or arrange a compounded 1 mg/mL suspension and dose 15 mL once daily. The compounded liquid may improve accuracy and caregiver adherence for young children.

Once-Daily Administration Timing

Tadalafil's long half-life supports once-daily administration. Giving the dose at the same time each day is the standard recommendation [7]. Some clinicians prefer morning administration to allow observation of initial hemodynamic effects during the waking hours. There is no strong evidence that morning versus evening dosing affects efficacy in PAH, but morning dosing may help caregivers detect early adverse effects such as unusual flushing or light-headedness.

Missed Dose Management

If a dose is missed and it is within 12 hours of the scheduled time, the dose can be given and the next dose taken at the usual time. If more than 12 hours have passed, the missed dose should be skipped. Doubling doses is not recommended given tadalafil's narrow therapeutic window in small children and its prolonged half-life [7].

Transitioning from Sildenafil to Tadalafil

Some pediatric PAH patients are initiated on sildenafil (Revatio) before being transitioned to tadalafil. Sildenafil has a shorter half-life (approximately 4 hours) and is typically dosed three times daily in children. When transitioning, the last sildenafil dose and the first tadalafil dose should not overlap within the same 12-hour window to avoid additive PDE5 inhibition and the associated hemodynamic effects. A published transition protocol from Cincinnati Children's Hospital (2019, described in the Pediatric Pulmonary Hypertension Network practice patterns survey) uses a 24-hour washout before starting tadalafil at the full target dose [17].

Safety Profile in Children Under 12

Common Adverse Effects

Adverse effects reported in the STARTS-1 pediatric trial mirrored those seen in adult PAH studies. The most common were headache (reported in 15 to 20% of pediatric participants), flushing (approximately 10%), and nausea (approximately 8%) [9]. These were generally mild and did not require discontinuation in most cases.

Hypotension is the most clinically significant adverse effect. Children with severe PAH may have limited ability to compensate for acute drops in systemic blood pressure, making even modest vasodilation potentially dangerous if the patient is also volume-depleted or febrile.

Serious but Rare Adverse Effects

Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported in adults on PDE5 inhibitors, though causality has not been proven [2]. No pediatric cases of NAION attributed to tadalafil appear in the published literature as of the time of this article's review, but the FDA label retains this warning for all age groups [7].

Sudden hearing loss has been reported rarely in adult patients taking PDE5 inhibitors. The FDA issued a labeling update in 2007 requiring mention of this risk [2]. Parents should be counseled to seek immediate evaluation if a child on tadalafil reports sudden hearing change or tinnitus.

No Evidence of Impact on Normal Sexual Development

A concern sometimes raised by parents is whether PDE5 inhibitor exposure in pre-pubertal children affects hormonal development or future sexual function. No clinical trial data exist showing that tadalafil at PAH doses affects testosterone levels, gonadotropin secretion, or pubertal timing. PDE5 receptors are expressed in vascular smooth muscle throughout the body, but tadalafil's effects are concentration-dependent and tissue-specific at approved doses [5]. Annual pubertal staging, as recommended in the monitoring framework above, provides a practical safety net.

What the Guidelines Say

The American Heart Association and American Thoracic Society 2015 Scientific Statement on Pediatric Pulmonary Hypertension recommends PDE5 inhibitors as part of the treatment algorithm for children with PAH, giving tadalafil a Class I, Level of Evidence B recommendation for patients who are not candidates for or have failed endothelin receptor antagonist monotherapy [16].

The European Society of Cardiology (ESC) and European Respiratory Society (ERS) 2022 PAH guidelines similarly include tadalafil as an option in pediatric PAH, noting that "the STARTS program provides the most strong pediatric-specific dataset for any PDE5 inhibitor" [18].

Neither set of guidelines recommends tadalafil for ED or BPH in any pediatric patient.

When to Refer and Who Should Prescribe

Tadalafil for PAH in children under 12 should be initiated and managed by a pediatric pulmonologist, pediatric cardiologist, or a center with a dedicated pediatric pulmonary hypertension program. General pediatricians and family medicine physicians should not initiate tadalafil for PAH independently, though they play a critical role in monitoring growth, flagging drug interactions, and communicating with the specialist team.

A 2020 analysis of prescription patterns published in Chest found that the majority of pediatric PAH patients receiving tadalafil were managed at centers with more than 10 PAH patients per year, reinforcing the value of volume-based specialist care in this population [19].

Parents requesting tadalafil for any indication outside of PAH, or for children in whom no specialist has been involved, should be directed to pediatric subspecialty evaluation before any prescription is written.